Track topics on Twitter Track topics that are important to you
Behavioral Disorders Drug Development Pipeline Review, 2017
This report provides an overview of the behavioral disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for autism, obsessivecompulsive disorder and attention deficit hyperactivity disorder and features dormant and discontinued projects.
Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history, fragile X syndrome, Tourette syndrome and epilepsy.
Obsessivecompulsive disorder OCD is characterized by unreasonable thoughts and fears obsessions that lead to do repetitive behaviors compulsions. Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again.
Finally, attention deficit hyperactivity disorder ADHD is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities.
The size of these pipelines ranges from 8 products in obsessivecompulsive disorder to 58 products in attention deficit hyperactivity disorder. Across all three of these indications, transporters and receptors of neurotransmitters such as dopamine, glutamine and serotonin, plus G proteincoupled receptors and ion channels, are the most common targets, closely reflecting the current treatment landscape of these diseases.
Which companies are the most active within the pipeline for behavioral disorder therapeutics?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important RD milestones and data publications to have happened in the field of behavioral disorders?
Reasons to buy
Understand the overall pipeline, with an ataglance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an uptodate overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...
Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. Attention deficit disorder (ADD) is a sub-type of ADHD - symptoms of ADHD include: a short attenti...